drugset / Trial / NCT06974617

Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine

NCT06974617

Recruiting 64 enrolled Cairo University
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.

Timeline

Start
2025-05-15
Primary completion
2025-10-01
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 100 iu Intramuscular
Subject Lidocaine Other / unclassified 2 ml Intranasal
Subject Lidocaine Other / unclassified 2 % Intranasal

Indications